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Abstract  
 
PURPOSE. Mitotane is the most broadly used systemic therapy for adrenocortical 
carcinoma (ACC), but its mechanism of action and possible predictors of treatment 
response are currently poorly defined. Our aim was to evaluate the gene expression of 
ribonucleotide reductase large subunit 1 (RRM1) and excision repair cross-
complementation group 1 (ERCC1) in ACC as potential biomarkers for clinical outcome 
and response to mitotane.   
EXPERIMENTAL DESIGN. Forty-five and 47 tissue samples from two cohorts 
(Orbassano, Italy; Wuerzburg, Germany) of completely resected ACC were centrally 
analyzed using Real Time PCR for RRM1 and ERCC1 expression. Fifty-four patients 
received surgery alone and 38 received adjuvant mitotane after surgery. Clinical and 
pathological features were highly comparable in the two series. H295R and SW-13 ACC 
cell lines were also used for pharmacological tests. 
RESULTS. ERCC1 gene expression was not associated to clinical outcome. In contrast, 
high RRM1 gene expression was associated to shorter disease-free and overall survival at 
both univariate and multivariate analysis. In patients with low RRM1 gene expression 
adjuvant mitotane was associated with improved disease free survival, whereas this effect 
was lost in cases with high RMM1 expression. In vitro mitotane induced strong up-
regulation of RRM1 transcription (up to 25-fold increase) in mitotane-insensitive SW-13 but 
not in mitotane-sensitive H295R cells. Furthermore, RRM1 silencing in SW-13 cells 
induced sensitivity to mitotane.  
CONCLUSION. Our in vitro and in vivo data indicate that RRM1 gene expression is 
functionally associated to mitotane sensitivity and support a possible role of RRM1 
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determination as a novel molecular biomarker predicting response to adjuvant mitotane in 
ACC.  
 
 
KEY WORDS:  adrenocortical carcinoma, RMM1, predictive marker, mitotane  
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Translational relevance 
 
Mitotane is the reference drug in the management of adrenocortical carcinoma (ACC) and 
is increasingly prescribed in an adjuvant setting. Serum mitotane levels are the only known 
predictive factor of efficacy. In the present paper, we observed in two independent series 
of radically resected ACC patients, that in patients with low ribonucleotide reductase large 
subunit 1 (RRM1) gene expression adjuvant mitotane was associated with improved 
disease free survival, whereas this effect was lost in cases with high RMM1 expression. 
Moreover, this observation was supported by data in adrenal cancer cell lines 
demonstrating that low responsiveness to mitotane was associated  to up-modulation of 
RRM1 gene and that selective RRM1 silencing can restore  mitotane sensitivity in vitro. 
The present data are of translational relevance since they generate the hypothesis that 
RRM1 gene expression is a genetic marker predicting mitotane efficacy that may be used 
to select patients who can benefit from adjuvant mitotane therapy. 
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Introduction 
 
Adrenocortical carcinoma (ACC) is a rare and aggressive malignant tumor.1-2 Surgery is 
the mainstay of therapy,3-4 however medical treatment has also an important role because 
a large proportion of ACC patients presents with metastatic disease and most of the 
radically resected patients relapse after surgery, often with metastases.5 Mitotane, either 
as monotherapy or in combination with cytotoxic chemotherapy, is the reference drug in 
the management of advanced ACC.6-7 
Mitotane has also been used in an adjuvant setting. A large retrospective multicentric 
study performed at several referral centers in Italy and Germany has shown that adjuvant 
mitotane therapy prolonged recurrence-free and overall survival in radically resected ACC 
patients8 and a panel of international experts recently recommended the administration of 
adjuvant mitotane in all patients at high risk of relapse.9 However, this recommendation 
based on retrospective data has a low level of evidence, whereas a prospective 
randomized controlled trial on adiuvant mitotane treatment is currently under way 
(www.adiuvo-trial.org). 
The risk of relapse or death in ACC patients may be assessed by several parameters, 
including pathological features, such as mitotic index,10-12 molecular alterations, such as 
TP53 mutations and beta-catenin dysregulation,13 or immunohistochemical markers 
including  matrix  metalloproteinase type 2 (MMP-2),14 glucose transporter 1 (GLUT1)15 
and steroidogenic factor-1 (SF-1).16 In addition, a gene signature profile has been shown 
to correlate more closely with prognosis than clinical data.17,18 However, in contrast to the 
availability of prognostic parameters, very few factors predicting the efficacy of treatment 
have been identified. A single study reported that a low immunohistochemical expression 
of excision repair cross-complementation group 1 (ERCC1) correlated to objective 
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response and overall survival in ACC patients treated with platinum-based 
chemotherapy.19 Concerning mitotane treatment, attainment of drug levels in the target 
range of 14-20 mg/L is the only factor predicting efficacy that has been convincingly 
demonstrated.20-22 
Since most ACC patients are at high risk of recurrence after primary surgery applying 
current prognostication methods,9 selection of patients for adjuvant therapy with mitotane 
based upon predictive factors for drug efficacy may represent a superior approach than 
selection based on prognostic markers. Such an approach is particularly appealing 
because mitotane therapy is a cumbersome and quite toxic treatment, that has to be 
maintained for years and needs frequent drug monitoring and a complex regimen of 
steroid replacement and management of adverse events.5,23   
We designed the present study stemming from the previous work of our research group on 
the role of genes involved in DNA repair or synthesis as predictors of response to 
chemotherapy in non-small cell lung cancer, neuroendocrine tumors and mesothelioma24-
26 and aimed to test the expression of ribonucleotide reductase large subunit 1 (RRM1) 
and ERCC1 genes in a cohort of ACC patients and to correlate gene expression with 
clinical outcome. The rationale for investigating RRM1 and ERCC1 genes as potential 
biomarker in ACC was based on their prognostic relevance in other cancer types27 and on 
the sequential use of platinum and gemcitabine-based therapy in ACC.28 In addition, we 
analyzed the predictive role of these two markers in patients treated with adjuvant 
mitotane and strengthened the in vivo results by in vitro analysis on ACC cell lines.   
 
Patients and methods 
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Patients. Ninety-two patients with ACC radically resected between 1989 and 2007 at the 
University of Turin at Orbassano (Turin), Italy (45 patients) and 35 centers in Germany all 
coordinated by the German ACC Registry (47 patients) were included according to the 
following: 1) age of 18 years or older; 2) histologically confirmed diagnosis of ACC after 
revision (MV, MP); 3) stage I to III disease, 4) complete tumor resection, 5) availability of 
follow-up information, 6) availability of representative paraffin-embedded tissue block(s). 
All patients fulfilling the inclusion criteria were included in the study. All German patients, 
during follow-up were transferred to the center in Würzburg. The diagnosis of ACC was based 
on established clinical and biochemical parameters29 and the pathological Weiss score30. 
Parameters recorded included age, sex, hormone secretion (according to ENSAT 
recommendations at www.ensat.org/acc.htm), ENSAT stage at diagnosis,31 initial 
therapeutic options including primary surgery, disease-free survival (DFS), defined by the 
time elapsing from diagnosis to either disease relapse or patient death, overall survival 
(OS), calculated from diagnosis till death, Weiss score, mitotic count, sites of metastases 
at the time of progression. Relapse was ascertained by computerized tomography (or 
magnetic resonance imaging) of chest and abdomen every 3-6 months. Disease relapse  
was defined as the appearance during follow-up of local recurrence or metastatic disease 
at imaging techniques. Adjuvant mitotane was offered to patients considered at high risk of 
relapse, in presence of the following criteria: 1) stage III ACC; 2) high mitotic index (the 
value of mitotic index prompting treatment ranged between 10 and 20 mitoses per 50 HPF among 
centers). When a post-operative adjunctive measure was deemed necessary, a monitored 
mitotane treatment aiming at plasma concentrations between 14 and 20 mg/l,20,21 was 
employed. In the absence of intolerability to mitotane, treatment was scheduled for at least 
2 years, or till ACC recurrence. All the patients received the same mitotane formulation 
(Lysodren, 500 mg tablets) that was purchased by Bristol-Meyers Squibb, USA, till 2003 
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and thereafter by Laboratoire HRA Pharma, France. Mitotane was given orally starting with 
1-2 g daily followed by progressive dose increments according to local protocols and 
patient compliance with the aim to reach concentrations between 14–20 mg/l. When such 
or even higher concentrations were attained, doses were tapered with further individual 
dose adjustments guided by the results of mitotane measurement and toxicity assessment. 
In the event of unacceptable side effects, the patients were allowed to return to a lower 
dose or discontinue mitotane temporarily restarting with a lower dose. Follow-up protocols 
were similar among the different centers including imaging of both chest and abdomen at 
baseline and thereafter every 3-6 months until disease progression or end of the study 
period. Follow-up procedures did not vary according to whether the patients received 
adjuvant mitotane or not. At each visit, the patients underwent physical examination, 
routine laboratory evaluation and hormonal work-up. Monitoring of mitotane concentrations 
was done in treated patients. For recurrent disease, radical surgery was performed if 
complete resection seemed feasible. In case of not resectable disease, mitotane naïve 
patients were treated with mitotane alone or in combination with cytotoxic drugs. In 
patients with recurrence during mitotane treatment, chemotherapy was added. Patients 
gave informed consent for collecting tissue and clinical data, and the study was approved 
by the ethics committees of both centres. 
 
Cell culture, siRNAs and pharmacological assays. NCI-H295R and SW-13 cell lines were 
supplied from the American Type Culture Collection (ATCC, Rockville, MD, USA). The 
H295R cells were cultured in a 1:1 mixture of Dulbecco's Modified Eagle's Medium and 
Ham's F-12 Nutrient mixture (DMEM/F12) (Sigma, St. Louis, MO, USA) supplemented with 
1% L- glutamine (Sigma, St. Louis, MO, Usa) and 2.5% of Nu-Serum (Becton Dickinson, 
San Jose, CA), and enriched with 1% of ITS+Premix (Becton Dickinson, San Jose, CA); 
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whereas SW-13 cells were cultured in DMEM (Sigma) supplemented with 10% fetal bovine 
serum (ATCC). Three human non-small cell lung cancer cell lines (two from 
adenocarcinoma - NCI-H520 and NCI-H1395, and one from squamous cell carcinoma -  
SKMES), also purchased from ATCC, were used as controls; all cells  were maintained in 
RPMI-1640 medium, supplemented with 10% FCS, 2mM L-glutamine, penicillin (25 
units/ml) and streptomycin (25 µg/ml, all from Sigma-Aldrich, St. Louis, MO, USA). For 
RRM1 silencing experiments in SW-13 cells, on-Target plus Smart Pool siRNAs targeting 
RRM1, on-Target plus Smart Pool siRNAs non-targeting and Siglo-Transfection indicator 
siRNA were used (Dharmacon® CO, USA). Interferin siRNA transfection reagent was 
purchased from Polyplus transfection (NY, USA). Transfection of SW-13 was first 
optimized by measuring the level of Siglo-green transfection indicator introduced with 
Interferin™, by flow cytometry using FACS Canto II (Becton Dickinson, San Jose, CA). 
Briefly, using a reverse transfection, siRNAs (at a final concentration of 100nM) and 
Interferin were diluted in DMEM without serum, and incubated for 10 min at room 
temperature. Lipoplexes were then transferred to multi-well tissue culture plates and, 
overlaid with 25x104 cells/well. After 24 h (cultured overnight), the medium was changed, 
and the cells were then cultured in medium alone (basal) or in medium containing different 
concentrations (1; 5; 10; 25; 50; 100 μM) of mitotane (Supelco, Sigma; dissolved in 100% 
methanol, Sigma), for 48h (SW-13) or 72h (H295R). These concentrations are in a range 
comparable to those reached in plasma levels in vivo. Cell viability was measured using 
WST-1 reagent (Roche Applied Science, Penzberg, Germany) following the supplied 
protocol.  
 
RNA isolation from paraffin embedded tissues and cell lines. Representative tumour areas 
were dissected under stereomicroscopic assistance from 10 μm sections of paraffin-
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embedded tissue in RNAse-free conditions. RNA isolation was performed by commercially 
available RNA extraction kits designed for paraffin material according to the 
manufacturer’s instructions (High Pure RNA Paraffin Kit; Roche Applied Science, Milano, 
Italy). Four samples of normal paraffin embedded adrenal tissue collected from 1 to 10 
year-old blocks were also analyzed in parallel and compared to a cDNA obtained from a 
commercial total RNA (Stratagene, La Jolla, CA). Total RNA from cell lines lysates was 
extracted using QIAzol lysis Reagent (Qiagen, Tokyo, Japan). Complementary DNA was 
transcripted using 500μg/ml oligodT (Roche Applied Science, Penzberg, Germany) and 
500M-MLV RT (200U/μl) (Invitrogen, Carlsbad, California) according to standard protocols. 
 
Quantitative real time PCR. Relative cDNA quantification for RRM1, ERCC1 and an 
internal reference gene (β-actin) was done in duplicate using a fluorescence-based real-
time detection method (ABI PRISM 7900 Sequence Detection System - Taqman; Applied 
Biosystems, Foster City, CA) using primers and probes previously published.26,32 To 
analyze target gene expression in individual tumors, the relative gene expression levels 
were expressed as ratios (differences between the Ct values) between two absolute 
measurements (genes of interest/internal reference gene). Then, the ΔΔCt values were 
calculated subtracting ΔCt values of each case to the value of the case with the lowest 
expression, and converting the ratio by the 2- ΔΔCt formula; cases were considered of low or 
high expression according to the median expression level obtained.  
 
Statistical analysis. Correlation between the expression of the two gene was tested using 
the Spearman’s method, differences of categorical variables were analyzed using the chi-
square test. DFS and OS survival curves were computed using the Kaplan-Meier method 
and compared using the log-rank test. Hazard ratios (HR) for disease progression and 
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patient death were estimated using the Cox proportional hazard model. Multivariate 
analyses were performed adjusting for patient age, sex, ACC stage, mitotic count, cortisol 
secretion. Cox models were also used to assess the presence of heterogeneity in the 
effect of marker expression in the different patient subgroups, defined by the covariates, 
by including in the model the appropriate treatment/covariate interaction term(s). In vitro 
efficacy of mitotane in non silenced and RRM1 siRNA SW-13 cells was measured by 
means of the F test. All p values reported are the result of two-sided tests. Statistical 
analyses were performed by using the SPSS for windows software (version 17). 
 
Results 
Patients. Both cohorts (Table 1) were comparable in terms of age, sex proportion, stage of 
disease, presence of clinical syndromes and tumor characteristics. Adjuvant mitotane 
therapy was administered to 18 Italian and 20 German patients, respectively; the 
remaining patients did not receive any post operative treatment. Target mitotane levels 
were reached in less than 40% of cases. The median follow-up was 66.3 months in all 
patients, and 80 and 62.8 months in the Italian and German cohorts, respectively. During 
follow-up, 29 patients of the Italian series (67.4%) and 35 of the German series (74.5%) 
developed disease recurrence while 28 (54.9%) and 23 (48.9%) patients, respectively, 
died of ACC progression. Mitotane treated patients had a longer DFS than patients 
followed up only: median 22.5 months [95% confidence interval (CI) 1.8-43.1] versus 13.2 
months (95% CI: 6.2-20.2), Hazard Ratio (HR) 0.70 (95% CI 0.43-1.16, p=0.17), and 
longer overall survival; median 154 months (95% CI 65.1-242.9) versus 53 months (95% 
CI 22.6-83.4), HR 0.63 (95% CI: 0.34-1.16, p=0.14).  
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Correlation between RRM1 and ERCC1 gene expression levels and patient/tumor 
characteristics. ERCC1 gene expression in normal adrenal tissues was rather low as 
compared to a commercially available total RNA pool, whereas RRM1 gene expression 
levels were comparable to reference total RNA. Moreover, the difference in RRM1 gene 
expression levels among normal tissues collected from paraffin blocks of different ages 
was in the range of 1-fold change (Figure 1), therefore showing that the time-frame of 
sample collection did not influence gene expression analysis. RRM1 and ERCC1 gene 
expression levels were reciprocally correlated in the patients’ study population 
(Spearman’s correlation test: R; 0.4425, p=0.0021). When dichotomized at the median 
value, both genes did not show any significant relationship with pathological features, 
except for the higher RRM1 expression levels in cases with a high mitotic count (<10 as 
compared to >10 mitoses in 50HPF, p=0.035).  
 
Relationship between RRM1 and ERCC1 gene expression and survival (Table 2). ERCC1 
gene expression was not associated with DFS and OS neither at univariate nor 
multivariate analysis. Conversely, high RRM1 expression levels were associated with 
shorter DFS both in univariate [p<0.0001] and multivariate analysis [p=0.002]. Similar 
results were seen for overall survival [univariate: p<0.0001; multivariate: p<0.0001]. 
Dividing patients according to each population, the prognostic role of RRM1 was more 
evident in German series than the Italian series (interaction test p=0.079), but similar 
results have been obtained in the two series in terms of survival (interaction test p=0.99).  
  
Relationship between RRM1/ERCC1 gene expression and outcome of adjuvant mitotane 
treatment. Patients attaining the target mitotane levels were similarly distributed between 
patients showing different RRM1 and ERCC1 expression. To test the predictive role of 
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RRM1 and ERCC1 gene expression in the adjuvant setting, patients treated with adjuvant 
mitotane or simply followed up were analyzed and stratified according to marker 
expression (dichotomised at the median value). In patients with low RRM1 expression, 
mitotane administration was associated with a significantly longer DFS than that of 
patients undergoing follow up only (Figure 2). The prognostic role of adjuvant mitotane 
therapy in patients with low RRM1 expression was maintained in multivariate analysis after 
adjustment for sex, age, stage and mitosis status [HR of recurrence 0.31 (95% CI: 0.13-
0.74); p=0.009], whereas no effect of  mitotane treatment on DFS was observed in 
patients with high RRM1 levels [adjusted HR of recurrence 0.87 (95% CI: 0.43-1.79); 
p=0.72] (Figure 2); the interaction test was close to attain the statistical significance 
(p=0.098). The HRs of recurrence in mitotane-treated patients compared to untreated 
patients with low RRM1 expression did not vary in the two patient cohorts considered 
separately: HR 0.36 (95% CI: 0.12-1.14, p=0.08) in the Italian series and HR 0.40 (95% 
CI: 0.11-1.47, p=0.17) in the German series (interaction test: p=0.83). The relationship 
between the prognostic role for DFS of adjuvant mitotane therapy and RRM1 expression 
was also explored dividing patients according to tertile distribution of RRM1. A step wise 
increase in the HR of adjuvant mitotane vs follow-up was observed:  HR 0.36, (95% CI: 
0.12-1.09, p=0.07) in the 1st tertile, HR 0.47 (95% CI: 0.19-1.13, p=0.09) in the 2nd tertile 
and HR 1.33 (95% CI: 0.63-2.79, p=0.45) in the 3rd tertile. These HRs were significantly 
different at the interaction test (p=0.034). Conversely adjuvant mitotane failed to be 
associated with overall survival either in patients with low RRM1 or in those with high 
RRM1 (figure 2), adjusted HR 0.50 (95% CI: 0.16-1.60, p=0.25) and 0.56 (95% CI: 0.25-
1.29, p=0.17), interaction test (p=0.98). As far as as ERCC1 is concerned, adjuvant 
mitotane therapy failed to be significantly associated with DFS in patients with low or high 
ERCC1 expression (figure 3), in multivariate analysis however adjuvant mitotane therapy 
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was significantly associated with lower risk of relapse HR 0.40 (95% CI: 0.18-0.90, 
p=0.026) in patients with low ERCC1 expression but not in those with high ERCC1 
expression, HR 0.65 (95% CI: 0.31-1.37, p=0.26), these two HRs were not different at the 
interaction test (p=0.79). Overall survival of mitotane treated patients was not significantly 
different than patients followed up only either in patients with low ERCC1 expression 
(figure 3), adjusted HR 0.47 (95% CI: 0.18-1.24, p=0.13) or in patients with high ERCC1 
expression, adjusted HR 0.63 (95% CI: 0.26-1.51), interaction test (p=0.94).  
     
 
RRM1 and ERCC1 modulation and interplay with mitotane responsiveness in vitro. The 
possible functional interaction between RRM1 and ERCC1 gene expression and mitotane 
responsiveness was tested in vitro in two established ACC cell line models, the H295R 
and SW-13 cells. Baseline ERCC1 gene expression was comparable in the two cell lines 
tested and was not modulated under mitotane administration (supplemental Figure 1). 
RRM1 gene expression levels were similar in H295R and SW-13 cells (data not shown). 
Mitotane  treatment  induced a dose-dependent reduction of  H295R cell viability and the 
H295R cells did not show significant changes in their RRM1 gene expression levels. 
Conversely, SW-13 cell viability was unaffected by mitotane but SW-13 cells displayed an 
impressive increase in RRM1 gene expression levels (up to 25 times over baseline in cells 
incubated with 25µM mitotane) (Figure 4). By contrast, control non-small cell lung cancer 
cell lines were not sensitive to mitotane treatment nor showed significant up-modulation of 
RRM1 gene under mitotane treatment (Figure 5). 
Thus, we inhibited RRM1 expression by RNA specific silencing (Figure 6). Efficiency of 
transfection measured by means of flow cytometry was optimal (not shown) and RRM1 
mRNA expression in SW13 cells was knocked down by RRM1 siRNA to less than 10% of 
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control cells transfected with non-targeting siRNAs. Silencing of RRM1 gene in SW-13 did 
not affect cell viability under basal conditions but induced a mitotane sensitivity indicating a 
direct link between RRM1 gene expression and anti-proliferative activity of mitotane in this 
cell model.  
 
Discussion 
Mitotane is the reference drug for treatment of advanced ACC and is increasingly adopted 
in an adjuvant setting.33-37 Demonstration of the adrenolytic effect of mitotane dates back 
to the fifties of the last century when studies demonstrated that administration of the drug 
was able to destroy the adrenal glands in animal models38,39 and to inhibit steroidogenesis 
at different enzymatic steps.23 However, the precise mechanism of action of mitotane 
remains still largely unknown, and it is generally thought that mitotane cytotoxicity is 
mediated through binding of the reactive acyl-chloride to mitochondrial proteins and 
subsequent oxidative damage through generation of free radicals.23,37 Recently, mitotane 
has been shown to sensitize H295R and SW-13 ACC cells to ionizing radiations by 
attenuating DNA repair and interfering with cell proliferation,40 data suggesting that 
mitotane, in addition to the assumed binding to proteins and phospholipids, may interact 
also with DNA, as was previously demonstrated in vitro.41 Moreover, it is known that 
metabolic activation is required for mitotane biological activity,37 but its metabolic pathway 
and the effective role of its metabolites, as well as its target molecules in tumor cells are 
far from being identified.  
For the first time, in the present study we provide in vitro and in vivo evidence of a 
relationship between RRM1 enzyme and the antineoplastic activity of mitotane in ACC. 
RRM1 is an enzyme involved in the synthesis of deoxyribonucleotides for DNA synthesis 
and represents the cellular target for gemcitabine, being its mRNA expression and genetic 
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variants predictive of response to gemcitabine treatment in patients with different types of 
cancer.27 
The present study includes two independent series of radically resected ACC patients  
recruited in two European countries.35 In the overall patient population, low RRM1 gene 
expression was significantly associated to longer disease-free and overall survival and this 
contrasts with other tumor models, such as non-small cell lung cancer, where low RRM1 
expression in patients treated with surgery is associated with reduced survival, whereas 
improved survival is observed in metastatic disease in gemcitabine-treated patients.42 
However, it should be noted that RRM1 may not be a direct target of mitotane and 
possible alternative molecular or metabolic interactions between mitotane and RRM1 are 
to be further evaluated to explain this apparent discrepancy. Moreover, in vitro analysis of 
control non-small cell lung cancer models showed that the anti-neoplastic mitotane 
efficacy as well as its effect in RRM1 gene modulation is specific for ACC cancer cell 
models (see also below). Subsequently, we tested if RRM1 gene expression affects the 
efficacy of adjuvant mitotane treatment, analyzing the DFS of patients treated with 
mitotane in the low and high RRM1 expression groups, respectively, in comparison to 
patients left untreated after surgery. Our results clearly indicate that mitotane efficacy was 
confined to the patients with low RRM1-expressing tumors, and this effect was evident 
also when the Italian and German cohorts were analyzed separately.  Despite the 
significant DFS prolongation in patients with low RRM1 expressing tumors, mitotane 
therapy was not able to significantly influence the overall survival.  Survival is affected by 
therapies administered upon progression and patients not receiving mitotane therapy in 
adjuvant setting received the drug at disease relapse, and this could have influenced the 
overall survival. 
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These data suggested a predictive role of RRM1 gene expression of mitotane efficacy in 
ACC and prompted a subsequent in vitro investigation in order to assess possible 
functional pharmacological interactions. Two established ACC cell lines were, therefore, 
analyzed for RRM1 gene expression levels at baseline and under mitotane treatment. 
Mitotane sensitivity in H295R cells was associated with a lack of RRM1 gene modulation, 
whereas SW-13 cells were not sensitive even at high doses of mitotane showing a 
significant and dose-dependent increase in RRM1 transcription following mitotane 
treatment. This observation was consistent with the data we obtained in vivo and supports 
the hypothesis that high RRM1 expression might impair the anti-neoplastic activity of 
mitotane. As a further step to establish a direct relationship between RRM1 and mitotane, 
RRM1 silencing was performed which sensitized SW-13 cells to mitotane, thus 
demonstrating that low RRM1 expression is of critical importance for mitotane antitumor 
efficacy. The lack of available tumor specimens sampled after mitotane treatment in the 
patient cohort prevented a subsequent tissue analysis to speculate the modulation of 
RRM1 in vivo; therefore the issue whether baseline RRM1 gene expression levels or 
rather its up-modulation under treatment are predictive of response to mitotane remains to 
be ascertained.  
ERCC1 gene expression levels were neither prognostic nor predictive of response to 
mitotane in our study population. The trend to significance of greater efficacy of mitotane 
treatment in patients with low ERCC1 expression is, in our opinion, most probably justified 
by the significant correlation between RRM1 and ERCC1 gene expression levels.  
Our study has certainly limitations and strengths. The retrospective nature of the study, the 
absence of randomization between mitotane treated and non treated patients and 
apparently relative small sample size might lead to  unknown  biases. However, when 
compared with the literature, our cohort seems to be quite representative for patients with 
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stage I-III ACC and we believe - acknowledging the rarity of the disease – that the sample 
size is one of the strength of this study. Moreover, the inclusion of two independent 
cohorts from different countries  favors the generalization of the present results . Although 
it might be surprising that less than half of the patients have been treated with mitotane in 
this cohort,. this may be explained by the fact that more than 80% of patients had surgery 
before the results of our adjuvant mitotane study have been published.43 Another strength 
of this study is the consistency of data on human tumors and cell culture in vitro 
experiments, providing new data that may help understanding the mechanism of action of 
mitotane and its target molecules.  
 
In conclusion, the present data represent the first evidence that RRM1 gene expression 
levels predict response to mitotane treatment in an adjuvant setting and are functionally 
associated to mitotane sensitivity. These findings suggest that the determination of RRM1 
gene expression may be of potential clinical utility to select patients for adjuvant mitotane 
therapy.  
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Figure legends 
 
Figure 1. RRM1 gene expression levels in samples of normal adrenal tissue stored for a 
variable period of time, as compared to a commercially available pool of total RNA.  
 
Figure 2. Influence of adjuvant mitotane on disease-free and overall survival of ACC 
patient population segregated according to RRM1 expression levels, evaluated using the 
Kaplan Meier curve estimation and univariate survival analysis (log-rank test).  
 
Figure 3. Influence of adjuvant mitotane on disease-free and overall survival of ACC 
patient population segregated according to ERCC1 expression levels, evaluated using the 
Kaplan Meier curve estimation and univariate survival analysis (log-rank test).  
 
Figure 4. Mitotane responsiveness (upper panels) and RRM1 gene expression under 
mitotane treatment (lower panels) in ACC cancer cells. Three replicate wells were used to 
determine each data point of cell viability measurements; for simplicity, mitotane values 
are represented in the X axis of the logarithmic curve as the effective concentrations; NT: 
untreated cells, corresponding to reference (1 unit of fold change). 
 
Figure 5. Mitotane responsiveness (left panels) and RRM1 gene expression under 
mitotane treatment (right panels) in non-small cell lung cancer cells. Three replicate wells 
were used to determine each data point of cell viability measurements; for simplicity, 
mitotane values are represented in the X axis of the logarithmic curve as the effective 
concentrations; NT: untreated cells, corresponding to reference (1 unit of fold change). 
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Figure 6. Influence of RRM1 gene expression levels on mitotane sensitivity. In mitotane-
insensitive SW-13 cells, RRM1 RNA silencing (RRM1 siRNA) reduced target gene 
expression but did not influence cell viability in the absence of mitotane; by contrast,  an 
increase in mitotane sensitivity was induced by RRM1 interference (F test comparing IC50 
doses of RRM1 siRNA and non-targeting siRNA control cells); for simplicity, mitotane 
values are represented in the X axis of the logarithmic curve as the effective 
concentrations. 
 
 






Table 1. Patients’ characteristics 
 
 Italian series German series 
No. 45 47 
Age – yrs 
median (range) 
 
46 (20-85) 
 
49 (18-77) 
Sex - No. (%) 
Male 
Female 
 
20 (44.4%) 
25 (55.6%) 
 
19 (40.4%) 
28 (59.6%) 
ENSAT Disease stage 
I 
II 
III 
 
  7 (15.6%) 
26 (57.8%) 
12 (26.6%) 
 
  4 (8.5%) 
23 (48.9%) 
20 (42.6%) 
Secreting tumor - No. (%) 
Non-secreting tumor 
Cortisol + androgens 
Androgens 
Estradiol 
Mineralcorticoids 
 
22 (48.9%) 
15 (33.3%) 
  4 (8.9%) 
  - 
  4 (8.9%)
 
28 (59.6%) 
12 (25.5%) 
  4   (8.5%) 
  3   (6.4%) 
 -  
Adjuvant mitotane - No. (%) 
Yes 
No 
 
18 (40.0%) 
27 (60.0% 
 
20 (42.5%) 
27 (57.5%) 
Patients with recurring ACC - 
No. (%) 
 
29 (67.4%) 
 
35 (74.5%) 
Weiss score 
Median (range) 
 
6 (4-9) 
 
5 (3-9) 
Mitoses in 50HPF - No. (%) 
<5 
6-10 
>10 
 
12 (26.7%) 
15 (33.3%) 
18 (40.0%) 
 
16 (34.0 %) 
  6 (12.8%) 
25 (53.2%) 
 
 
 
 
 
Table 2. Prognostic role of ERCC1 and RMM1 expression in the series of 92 ACC. 
 
 Univariate 
HR (95% CI) 
p Multivariate 
HR (95% CI) 
p 
Disease Free 
Survival 
    
High ERCC1  1.31 (0.81-2.13) 0.27 0.97 (0.57-1.64) 0.91 
High RRM1  2.60 (1.57-4.30) <0.0001 2.31 (1.36-3.95) 0.002 
     
Overall Survival     
High ERCC1  1.25 (0.71-2.21) 0.44 0.98 (0.52-1.85) 0.96 
High RRM1  3.19 (1.73-6.00) <0.0001 3.59 (1.85-6.96) <0.0001 
     
ERCC1 and RRM1 expression was categorized at the median value.  
